Steven Cook Sells 6,800 Shares of Omada Health (NASDAQ:OMDA) Stock

Omada Health, Inc. (NASDAQ:OMDA) CFO Steven Cook sold 6,800 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $17.23, for a total transaction of $117,164.00. Following the sale, the chief financial officer directly owned 187,209 shares in the company, valued at $3,225,611.07. This trade represents a 3.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Omada Health Price Performance

Shares of NASDAQ:OMDA opened at $17.25 on Thursday. The company’s 50-day moving average price is $15.63 and its two-hundred day moving average price is $14.79. Omada Health, Inc. has a one year low of $10.28 and a one year high of $26.92. The stock has a market capitalization of $1.03 billion and a PE ratio of -63.89.

Omada Health (NASDAQ:OMDA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.03. Omada Health had a negative net margin of 2.22% and a negative return on equity of 1.82%. The firm had revenue of $78.05 million for the quarter. On average, analysts anticipate that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on OMDA. JPMorgan Chase & Co. cut their price target on shares of Omada Health from $32.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, March 12th. Barclays upped their target price on shares of Omada Health from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Wall Street Zen cut shares of Omada Health from a “buy” rating to a “hold” rating in a report on Saturday, May 30th. BMO Capital Markets dropped their target price on shares of Omada Health from $27.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, March 6th. Finally, Citizens Jmp upped their target price on shares of Omada Health from $18.00 to $21.00 and gave the company a “market outperform” rating in a report on Friday, May 8th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $22.91.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of OMDA. Geode Capital Management LLC bought a new position in Omada Health in the 2nd quarter valued at about $637,000. Walleye Capital LLC bought a new position in Omada Health in the 2nd quarter valued at about $458,000. Ilex Capital Partners UK LLP bought a new position in Omada Health in the 2nd quarter valued at about $201,000. Soros Fund Management LLC bought a new position in Omada Health in the 2nd quarter valued at about $640,000. Finally, Raymond James Financial Inc. bought a new position in Omada Health in the 2nd quarter valued at about $32,000.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.